Actinogen Medical (ASX: ACW) is an Australian biotechnology company developing novel therapeutics for Alzheimer's disease and related cognitive disorders by targeting brain cortisol via inhibition of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). The company's lead compound, Xanamem® (also known as emestedastat or XOC-001), represents a novel approach to neuroprotection by reducing excessive cortisol activity in the brain, a pathway increasingly recognized as a key contributor to neurodegenerative processes [1][2].
The company was founded in 2005 as pHarma Biotechnology and renamed to Actinogen Medical in 2015 to reflect its expanded focus on brain-penetrant 11beta-HSD1 inhibitors. Headquartered in Sydney, New South Wales, Australia, Actinogen is conducting one of the most advanced clinical programs targeting the glucocorticoid system in Alzheimer's disease, with its pivotal XanaMIA Phase 2b/3 trial enrolling patients with early Alzheimer's disease [1].
| Attribute | Value |
|-----------|-------|
| Founded | 2005 (as pHarma Biotechnology) |
| Headquarters | Sydney, New South Wales, Australia |
| Ticker | ACW (ASX) |
| CEO | Dr. Alan Pearson |
| Market Cap | ~$50M AUD (2025) |
| Employees | ~20-30 |
| Status | Public (ASX listed) |
Actinogen Medical was founded in 2005 in Melbourne, Australia, under the name pHarma Biotechnology, with a focus on developing 11β-HSD1 inhibitors for metabolic diseases. The company's early research established the scientific foundation for targeting 11β-HSD1 in the brain, recognizing that locally produced cortisol within the hippocampus and prefrontal cortex could have distinct effects from systemic cortisol levels [3].
The transition from metabolic indications to CNS indications required significant scientific insight. Research demonstrated that 11β-HSD1 is expressed in key brain regions involved in memory and cognition, including the hippocampus, amygdala, and prefrontal cortex. Unlike systemic cortisol production, brain 11β-HSD1 activity is regulated by local factors and may contribute to cortisol excess specifically within neural tissue without affecting systemic hormone levels [4][5].
In 2015, the company changed its name to Actinogen Medical to reflect its strategic focus on central nervous system disorders. The XanADu Phase 2 clinical trial was initiated in 2020, evaluating Xanamem in patients with early Alzheimer's disease. This trial represented the first large-scale clinical validation of 11β-HSD1 inhibition in AD patients [6].
The XanADu trial completed in 2023, showing some evidence of cognitive benefit in certain patient subgroups, although the trial missed its primary endpoint in the overall population. Subgroup analyses suggested that patients with higher baseline cognitive impairment or specific genetic profiles may have derived greater benefit, providing a foundation for the subsequent XanaMIA trial design [6][7].
The XanaMIA Phase 2b/3 trial initiated in 2024, representing a pivotal registration-enabling study for Xanamem in early Alzheimer's disease. The trial uses a more enriched patient population based on learnings from XanADu, with topline results expected in late 2026 [1][2].
In 2025, Actinogen successfully completed a capital raising of $16.8 million through a placement and share purchase plan, providing funding beyond the XanaMIA topline results. The company also received $7.4 million in R&D tax rebates, supporting continued clinical development [1].
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a bidirectional enzyme that primarily acts as a reductase in vivo, converting inactive cortisone to active cortisol [3][4]. This enzyme is widely expressed in peripheral tissues (liver, adipose tissue, muscle) where it contributes to metabolic syndrome and insulin resistance. However, 11β-HSD1 is also expressed in the brain, particularly in the hippocampus, amygdala, hypothalamus, and prefrontal cortex—regions critical for memory, emotion regulation, and executive function [4][5].
Within the brain, 11β-HSD1 operates independently from the hypothalamic-pituitary-adrenal (HPA) axis, allowing for local regulation of cortisol levels without affecting systemic hormone concentrations. This local production of cortisol has been termed "intracrine" signaling, where cells produce their own cortisol from circulating inactive precursors [4].
Elevated cortisol levels have been strongly implicated in the pathogenesis of Alzheimer's disease through multiple mechanisms [3][8]:
Amyloid-Beta Production: Cortisol increases amyloid-beta production through upregulating beta-secretase (BACE1) expression and activity. In neuronal cell cultures, cortisol treatment increases amyloid precursor protein (APP) processing toward the amyloidogenic pathway, leading to increased amyloid-beta 40 and amyloid-beta 42 production [8].
Tau Phosphorylation: Cortisol promotes tau protein hyperphosphorylation through activation of several kinases including GSK-3β and CDK5. Hyperphosphorylated tau forms neurofibrillary tangles, a core pathological hallmark of Alzheimer's disease. Studies in mouse models demonstrate that chronic cortisol exposure increases tau pathology in the hippocampus [9][10].
Synaptic Dysfunction: Cortisol impairs synaptic plasticity through multiple mechanisms. It reduces long-term potentiation (LTP) in hippocampal slices, decreases dendritic spine density, and interferes with NMDA receptor function. These effects on synaptic plasticity directly impact memory formation and consolidation [11][12].
Hippocampal Atrophy: The hippocampus is particularly vulnerable to cortisol toxicity. Chronic cortisol exposure leads to dendritic atrophy, reduced neurogenesis, and neuronal loss in the hippocampus. Human imaging studies demonstrate that elevated cortisol levels correlate with reduced hippocampal volume in both aging and Alzheimer's disease populations [5][13].
Neuroinflammation: Cortisol modulates neuroimmune responses, with chronic exposure leading to increased pro-inflammatory cytokine production in the brain. Microglial activation and neuroinflammation are established contributors to neurodegenerative processes [14].
Xanamem works by inhibiting 11β-HSD1 in the brain, reducing local cortisol production without significantly affecting systemic cortisol levels. This targeted approach avoids the adverse effects associated with global glucocorticoid suppression, such as adrenal insufficiency and immune suppression [3][15].
The drug is designed to cross the blood-brain barrier efficiently, with preclinical studies demonstrating brain penetration and target engagement in relevant CNS regions. The selectivity profile minimizes inhibition of 11β-HSD2, an isozyme that primarily acts in the kidney to convert active cortisol to inactive cortisone, preventing mineralocorticoid excess [15][16].
| Trial | Phase | Status | Patients | Primary Endpoint |
|-------|-------|--------|----------|------------------|
| XanADu | Phase 2 | Completed (2023) | ~120 | CDR-SB change |
| XanaMIA | Phase 2b/3 | Enrolling | ~330 | CDR-SB change |
The XanaMIA Phase 2b/3 trial is the pivotal study for Xanamem in early Alzheimer's disease. The trial enrolled patients with mild cognitive impairment (MCI) due to AD or mild Alzheimer's disease dementia, confirmed by amyloid positivity on PET imaging or cerebrospinal fluid biomarkers [2].
Key design features of XanaMIA:
Major depressive disorder (MDD) is associated with HPA axis hyperactivity and elevated cortisol levels. Approximately 30-50% of patients with MDD show cortisol hypersecretion, and this subgroup may particularly benefit from cortisol-reducing interventions [17][18].
Actinogen is developing Xanamem for cognitive impairment associated with MDD, targeting patients who have persistent cognitive symptoms despite mood stabilization. Cognitive dysfunction in depression includes impaired attention, working memory, and executive function, which may be mediated in part by glucocorticoid toxicity in the hippocampus and prefrontal cortex [17][18].
Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and a leading single-gene cause of autism. Patients with FXS commonly exhibit cortisol dysregulation, and preclinical models suggest that excess cortisol signaling contributes to the cognitive and behavioral phenotype [19].
A Phase 2 trial of Xanamem in Fragile X Syndrome is evaluating the drug's effects on anxiety, sleep, and behavioral problems. The rationale is based on observations that patients with FXS often show elevated basal cortisol and altered stress responses, which may be amenable to 11β-HSD1 inhibition [19].
Preclinical studies of Xanamem demonstrate robust efficacy in multiple models:
Cognitive Performance: In aged rodents, Xanamem treatment improved performance in hippocampal-dependent memory tasks including Morris water maze and object recognition. These effects were associated with reduced 11β-HSD1 activity and cortisol levels in the hippocampus [15][16].
Amyloid Pathology: In APP/PS1 transgenic mice modeling Alzheimer's disease pathology, Xanamem reduced amyloid-beta plaque load and improved cognitive function. The mechanism involves reduced amyloid-beta production through decreased BACE1 activity [8][15].
Tau Pathology: In tau transgenic models, Xanamem reduced tau phosphorylation and aggregation. The effect was mediated through modulation of glucocorticoid-responsive kinases including GSK-3β [9][15].
Synaptic Function: Electrophysiological studies demonstrated that Xanamem treatment enhanced long-term potentiation in hippocampal slices from aged animals, with effects reversed by glucocorticoid receptor antagonists [11][15].
Actinogen occupies a unique position in the Alzheimer's disease therapeutic landscape by targeting the cortisol system. Competitors in related mechanisms include:
Actinogen has established collaborations with academic institutions to advance its pipeline:
As of 2025, Actinogen has secured funding through:
Xanamem has received:
Actinogen's development strategy includes:
The hippocampus expresses high levels of 11β-HSD1, particularly in the CA1 and dentate gyrus regions. This localized expression creates a microenvironment where cortisol levels can be regulated independently from systemic glucocorticoid concentrations. The enzyme is primarily expressed in glial cells and neurons, with activity concentrated in regions rich in glucocorticoid receptors [4][5].
In the hippocampus, 11β-HSD1 plays a dual role in glucocorticoid signaling:
The prefrontal cortex is another key region expressing 11β-HSD1, involved in executive function, working memory, and decision-making. Glucocorticoid excess in this region contributes to:
While the hypothalamus expresses lower levels of 11β-HSD1 compared to the hippocampus, the enzyme still plays a role in feedback regulation of the HPA axis. Local cortisol production in the hypothalamus can affect:
Actinogen has developed biomarker strategies to identify patients most likely to benefit from 11β-HSD1 inhibition:
Genetic Markers:
The XanaMIA trial uses multiple cognitive assessment tools:
Primary Endpoint:
Based on Phase 1 and Phase 2 studies, Xanamem has demonstrated an acceptable safety profile:
Common Adverse Events:
The Alzheimer's disease therapeutic market represents one of the largest opportunities in pharmaceutical development:
Xanamem's unique positioning compared to approved anti-amyloid antibodies:
| Feature | Xanamem | Anti-Amyloid Antibodies |
|---------|---------|-------------------------|
| Mechanism | 11β-HSD1 inhibition | Amyloid-beta clearance |
| Route | Oral | IV infusion |
| Dosing | Once daily | Monthly infusion |
| Target | Cortisol pathway | Amyloid pathology |
| Staging | Early AD | Early AD |
| Safety | Clean profile | ARIA risk |
Actinogen has established manufacturing capabilities for Xanamem:
Actinogen's IP portfolio protects the Xanamem program:
| Milestone | Status | Timeline |
|-----------|--------|----------|
| FDA Fast Track Designation | Granted | 2024 |
| FDA Orphan Drug Designation (FXS) | Granted | 2023 |
| TGA Priority Review | Granted | 2024 |
| XanaMIA Phase 2b/3 start | Complete | 2024 |
| XanaMIA topline results | Expected | Q4 2026 |
| FDA submission | Planned | 2027 |
The following diagram shows the key molecular relationships involving Actinogen Medical discovered through SciDEX knowledge graph analysis: